Skip to main content
Premium Trial:

Request an Annual Quote

Michael Savage, Arnold Levine, Gregory Abbott, Jon Saxe, Randy Scott.

Premium

Genomica of Boulder, Colo., has appointed Michael Savage to its board of directors. Savage was CEO of Molecular Simulations from 1991 until the company was acquired by Pharmacopeia in 1998 and is currently principal of Savage Consulting.

Savage will fill the board seat being vacated by Arnold Levine, president of Rockefeller University and a scientific trustee of Cold Spring Harbor Laboratory, who is joining the company’s scientific advisory board.

Gregory Abbott and Jon Saxe have been appointed to the board of directors of diaDexus of Santa Clara, Calif.

Abbott is the managing partner of the Seattle office of law firm Cooley Godward and previously served as CEO at Synergen, acquired by Amgen; Darwin Molecular, acquired by Chiroscience; and AlphaGene.

Saxe currently sits on the boards of several companies and served as president of Protein Design Labs and Saxe Associates and president and CEO of Synergen. Saxe takes the place of Randy Scott, who stepped down to focus on his new company, Genomic Health.

Filed under

The Scan

Push Toward Approval

The Wall Street Journal reports the US Food and Drug Administration is under pressure to grant full approval to SARS-CoV-2 vaccines.

Deer Exposure

About 40 percent of deer in a handful of US states carry antibodies to SARS-CoV-2, according to Nature News.

Millions But Not Enough

NPR reports the US is set to send 110 million SARS-CoV-2 vaccine doses abroad, but that billions are needed.

PNAS Papers on CRISPR-Edited Cancer Models, Multiple Sclerosis Neuroinflammation, Parasitic Wasps

In PNAS this week: gene-editing approach for developing cancer models, role of extracellular proteins in multiple sclerosis, and more.